|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First - line Therapy for Non- squamous Non - Small~ Lung Cancer显示文摘 | Patel JD Hensing TA Rademaker A | 2009 | Clin Oncol2009，27，20： | 1 |
| 2 | The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced stage Ⅲb or Ⅳ nonsmall cell lung carcinoma treated with carboplatin and paclitaxel显示文摘 | Hensing TA Peterman AH Schell MJ | 2003 | Cancer2003，98，4： | 1 |
| 3 | Clinical evaluation and staging of patients who have lung cancer显示文摘 | Hensing TA | 2005 | Hernatol Oncol Clin N Am2005，19，： | 1 |
| 4 | The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage ⅢB or Ⅳ non-small cell lung carcinoma treated with carboplatin and paclitaxel 显示文摘 | Hensing TA Peterman AH Schell M J | 2003 | Cancer2003，98，4： | 1 |
| 5 | The impact of age on toxicity,response rate,quality of life,and survival in patients with advanced stage Ⅲb or Ⅳ non-small cell lung carcinoma treated with carboplatin and paclitaxel显示文摘 | Hensing TA Peterman AH Schell MJ | 2003 | Cancer2003，98，4： | 1 |
| 6 | Molecular biomarkers for future screening of lung cancer显示文摘 | Hensing TA Salgia R | 2013 | J Surg Oncol2013，108，： | 1 |
| 7 | Clinical evaluation and staging of patients who have lung cancer显示文摘 | Hensing TA | 2005 | Hernatol Oncol Clin North Am2005，19，2： | 1 |
| 8 | The impact of age on toxicity,response rate,quality of life,and survival in patients with advanced stage Ⅲ b or Ⅳ nonsmall cell lung carcinoma,treated with carboplatin and paclitaxel显示文摘 | Hensing TA Peterman AH Schell MI | 2003 | Cancer2003，98，： | 1 |
| 9 | PhaseⅡstudy of pemetrexed and carboplatin plus bevacizumabwith maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer显示文摘 | Patel JD Hensing TA Rademaker A | 2009 | J Clin Oncol2009，27，20： | 1 |
| 10 | The impact of age on toxicity,response rate,quality of life,and survival in patients with advanced stage III b or IV non small cell lung carcinoma treated with carboplatin and paclitaxel显示文摘 | Hensing TA Pelemmn AH Schell MJ | 2013 | Cancer2013，98，： | 1 |
| 11 | The impact of age on toxicity,response rate,quality of life,and survival in patients with advanced,Stage IIIB or IV non small cell lung carcinoma treated with carboplatin an paclitaxel显示文摘 | Hensing TA Peterman AH Schell MJ | 2003 | Cancer2003，98，4： | 1 |
| 12 | The role of induction therapy in the management of resectable non-small cell lung cancer显示文摘 | Hensing TA Detterbeck FC Socinski MA | 2000 | Cancer Control2000，7，： | 1 |
| 13 | Molecular biomarkers for future screening of lung cancer显示文摘 | Hensing TA Salgia A | 2013 | J Surg Oncol2013，108，： | 1 |
| 14 | The impact of age on toxicity,response rate,quality Of life,and survival in patients with advanced stage m B or Ⅳ nonsmall cell lung carcinoma treated with carboplatin and paclitaxel 显示文摘 | Hensing TA Peterman AH Schell MJ | 2003 | Cancer2003，98，： | 1 |
| 15 | Phase Ⅱ study of pemetrexed and carboplatin plus bevaeizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer 显示文摘 | Patel JD Hensing TA Rademaker A | 2009 | J Clin Oncol2009，27，20： | 1 |
| 16 | Clinical evaluation and staging of patients who have lung cancer 显示文摘 | Hensing TA | 2005 | Hernatol Oncol Clin N Am2005，19，2： | 1 |
| 17 | The feasibility ofadjuvant carboplatin and docetaxel in patients with curatively resectednon-small cell lung cancer显示文摘 | Stinchcombe TE Harper HD Hensing TA | 2008 | J Thorac Oncol2008，3，2： | 1 |
| 18 | Clincal evaluation and staging of patients who have lung cancer 显示文摘 | Hensing TA | 2005 | Hematol Oncol Clin North Am2005，19，： | 1 |
| 19 | The impact of age on toxicity, response rate ,quality of llfe and survival in patients with advanced stage Ⅲ b or IV non-small cell lung carcinoma treated with carboplatin and paditaxel 显示文摘 | HENSING TA PETERMAN AH SCHELL MJ | 2003 | Cancer2003，98，4： | 1 |
| 20 | Pemetrexed and carboplatin plus bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer:preliminary safety results of a phase Ⅱ trial显示文摘 | Patel JD Hensing TA Keeffe PO | 2006 | Am Soc Clin On col2006，，17： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员